

Supplementary Table 1. Primers used in this study.

CD33	direct	5'-GGTCAAAGTTCAGTGCCTTCCTC-3'
	reverse	5'-TTGAGCATTTAAAACCCCAAAGC-3'
Siglec-E	direct	5'-CTCAGTGCTAACCATCACCCCT-3'
	reverse	5'-ATGACACGTTTAGACGGGTGG-3'
Siglec-F	direct	5'-CCCTGCCTCCACCATAAATGA-3'
	reverse	5'-CATAGTGGAGTTCAGGCTCATC-3'
Siglec-G	direct	5'-GAAAATGGCTTAACCGTTCCC-3'
	reverse	5'-TCCGGAAGAAATAGTTTGTTGAGTC-3'
Siglec-H	direct	5'-CACCCAGCACTCAAACCTACA-3'
	reverse	5'-AAGGACAGGCATCAGAATAAGG-3'
HPRT	direct	5'-CCAGCGTCGTGATTAGCGAT-3'
	reverse	5'-TGGCCTCCCATCTCCTTCAT-3'
iNOS	direct	5'-CTTGGAGCGAGTTGTGGATTGTC-3'
	reverse	5'-ATTGTACTCTGAGGGCTGACACA-3'
IL-10	direct	5'-AGCCGGAAGACAATAACTGC-3'
	reverse	5'-AACCCAAGTAACCCTTAAAGTCCTG-3'
TNF- α	direct	5'-CAAATTCGAGTGACAAGCCTG-3'
	reverse	5'-ACAAGGTACAACCCATCGGC-3'
STAT5	direct	5'-CCATGTCCCAGAAGCACCTT-3'
	reverse	5'-AAACTGAGCTTGGATCCGCA-3'
IL-5 receptor α chain	direct	5'-CTGGGACCCAAATCCTGACC-3'
	reverse	5'-TGGCCAGAGTTGTATGGCTG-3'
GATA1	direct	5'-TTGGGATCACCCCTGAACTCG-3'
	reverse	5'-AGAATCCACAAACTGGGGCA-3'
I-A ^b α chain	direct	5'-CAGGAGTCAGAAAGGACCTCG-3'
	reverse	5'-ACTGGCAGTCAGGAATTCGG-3'

Supplementary Table 2. siRNAs used in this study.

Siglec-F #1	5'-GACACAGGAACUAAAGUCCUGCAGA-3' 5'-UCUGCAGGACUUUAGUCCUGUGUC-3';
Siglec-F #2	5'-UCCACCAUAAAUAGUGCAAGCAUAA-3' 5'-UUAUGCUUGCACUAUUUAUGGUGGA-3';
Siglec-F #3	5'-GCAGCUACGAAAGGCAACCAUCUUG-3' 5'-CAAGAUGGUUGCCUUUCGUAGCUGC-3'.
STAT5	5'-CCCACUUCAGAAACAUGUCACUGAA-3' 5'-UUCAGUGACAUGUUUCUGAAGUGGG-3'.
